What we do Mercury Laboratories Limited manufactures and exports pharmaceuticals specializing in mother and child healthcare products, focusing on gynae and pediatrics segments. |
Founded in 1,962 |
Market share Well-positioned in the niche mother and child healthcare pharmaceutical sector with growing export presence. |
Problem solved Offers essential medicines for maternal and pediatric health, addressing critical healthcare needs. |
Top clients or who we serve Serves government institutions, semi-government bodies, hospitals, clinics domestically and internationally. B2B and B2C mix. |
Key management Rajendra R. Shah (Managing Director) is a key leadership figure with over four decades of industry experience. |
Our journey and innovations From a partnership in 1962 to new GMP-compliant facilities in 2015-16, with continuous product launches expanding therapeutics. |
Where we operate Domestic India and export markets with growing contribution from international sales. |
Top products or what we offer Wide range of pharmaceuticals focused on mother and child care, including new drugs introduced in recent years. |
Top brands Teclobet, Tanolite, Clinzit, Levotryl series, THA series, Pyloryl, Pangs At, Feveryl Drops—all key revenue drivers. |
Raw materials needed Pharmaceutical ingredients and chemicals required for formulation manufacturing. |
Raw materials supplier Supplied by trusted vendors, both domestic and international, specifics undisclosed. |
Recurring vs cyclical contribution Revenue includes recurring sales domestically and growing export business, partly cyclical due to regulatory and market factors. |
Our industry position Niche leader in mother and child pharma segment with steady export growth and expanding institutional business. |
Financial highlights Revenue Rs 75.1 crore, Net Profit Rs 3.14 crore in FY 2024-25; minor revenue decline but export growth of 11.4%. |
Geographical revenue split Domestic sales contribute 72%, exports 28%, with exports growing strongly. |
Order book - |
Whats driving growth New product launches, institutional tie-ups, export growth, and enhanced manufacturing capacity. |
Our future plans Expand production capacity, develop new formulations, strengthen global exports and institutional sales. |
Our green promise Undertakes safety and environmental training; details on sustainability practices implicit in manufacturing processes. |
Our people and values About 503 employees with emphasis on training, safety, and inclusive workplace culture. |
Key challenges ahead Drug price controls, generic competition, raw material supply risks, currency fluctuations, and regulatory challenges. |
Interesting facts Operates since 1962; introduced world-class GMP facilities meeting WHO standards; focus on mother and child health niche. |
Risks and strategy Manages risks via diversified sourcing, internal controls, regulatory compliance and strategic export focus. |
